Se infatti l'eventualità che il tasso ufficiale scenda sui valori limite viene data dagli economisti al 2,7%, l'adozione delle regole sul capitale indicate dal Comitato di Basilea per la vigilanza bancaria può diminuire ulteriormente questa probabilità di oltre un quarto, riducendo anche le fluttuazioni del ciclo. Fermato uomo con problemi mentali », Boris Johnson discendente della mummia di Basilea. Si tratta del più antico e... Articolo completo »   Che ne pensi? La passione per le discendenze genealogiche del ministro degli Esteri britannico è destinata ad essere ancora più alimentata da una... Articolo completo »   Che ne pensi? Attenzione: non è possibile salvare due documenti uguali nella stessa cartella con lo stesso titolo. T: +41 61 606 11 11 Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022 Read more Download Jun 24. Il gruppo elvetico produce un principio attivo necessario per il vaccino anti coronavirus di Moderna e con la società Usa il gruppo di Basilea ha firmato all'inizio di maggio un accordo di cooperazione ... Lonza produce un principio attivo necessario per il vaccino anti coronavirus di Moderna e con la società Usa il gruppo di Basilea ha firmato all'inizio di maggio un accordo di cooperazione. Le tele saranno analizzate in vista della mostra del padre dell'Astrattismo geometrico prevista per l'estate del 2022, Per la società quotata, titolare di ArtBasel, le perdite per 24,4 milioni di franchi e un'azione legale potrebbero ritardare o vanificare l'investimento di James Murdoch, La fondatrice del marchio di abbigliamento JNBY si definisce una "collectaholic" e. Il suo prossimo progetto a Hangzhou è un hub espositivo, residenziale ed educativo, firmato da Renzo Piano, Aggiungi il documento al tuo spazio My24 oppure accedi all'area >>, Inserisci il titolo con cui vuoi visualizzare il documento nella tua cartella di My24. PO Box Il presidente del Sion: "Fermiamo tutto! Basilea Pharmaceutica Ltd. », Sei persone sono rimaste ferite, di cui una gravemente, ieri sera nel corso di due incidenti avvenuti quasi contemporaneamente a Basilea nell'ambito della Fiera d'autunno. Switzerland ", Svizzera: proteste a Berna, Zurigo, Basilea e San Gallo, Francia. ROMA - Terremoto in Svizzera, un'apparente anomalia: le Alpi sono zona sismica. La polizia ha controllato... Articolo completo »   Che ne pensi? », Svizzera, due uomini sono entrati al Cafè 56 e hanno aperto il fuoco. Lo scambio sblocca l’affare, Oroscopo Paolo Fox, previsioni astrali 18 novembre 2020 per tutti i segni: Cancro irruento. Tutte le notizie in tempo reale solo sul sito TgCom24.it. 6 aggiornamenti sono stati effettuati durante l'ultimo minuto. Sette persone rimaste ferite in un attacco alla stazione. In... Articolo completo »   Che ne pensi? », I lavori per Basilea 4 sono sostanzialmente conclusi. Monete digitali, troppi ritardi decisionali, La Fondation Beyeler passa ai raggi X i suoi sette Mondrian, Conti in rosso per MCH Group SA che va a caccia di nuovi business, Wall Street: indici incerti ma settimana positiva, Dj +0,2%, Nasdaq -0,1%, Petrolio: +0,6% a New York, chiude a 57,43 dlr, +8,8% in settimana (RCO), Dl crescita: via libera dalla Camera con 270 si', passa all'esame del Senato, Wall Street: Elizabeth Warren contro carceri private, giu' titoli settore, Borsa: lunedi' oltre 2mld dividendi in arrivo, -0,3% impatto su Ftse Mib, Arriva la nuova Imu, fusione di quella attuale con la Tasi, Decreto crescita: tutte le novità del testo dopo l’ok della Camera, Cedolare secca, affitti brevi e Imu: cosa cambia con il decreto crescita, Il fondo H2O di Natixis nel caos, tra i sottoscrittori molti italiani, Oro e petrolio, rialzi da record grazie a Fed e tensioni Usa-Iran. Secondo il Servizio sismico elvetico l'evento più forte registrato fu a Basilea nel 1356. Il presidente del Sion: "Fermiamo tutto! La manifestazione che ha riscosso maggior... Articolo completo »   Che ne pensi? ... Nel 2002 il quartier generale si è spostato a Basilea. Ultime Notizie Basilea Di seguito gli articoli di tutte le ultime Basilea news. », Basilea: in consiglio comunale col figlio neonato: cacciata - Succede all'assemblea municipale di Basilea Città. Fermato uomo con problemi mentali, Svizzera: sparatoria in un bar di Basilea. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma, Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB), Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific, Basilea reports on commercial progress of antifungal Cresemba® in Europe, Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor, Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea. Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel, Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs, Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel, Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel, Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada, Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole, Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma, Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting, Basilea names new member of its Extended Management Committee, Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders, Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections, Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab, Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors, Basilea reports solid 2016 results and expects to double product sales in 2017, Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients, Basilea's antifungal Cresemba® (isavuconazole) launched in France, Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries, Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma, Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America, Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553, Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region, Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets, Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy, Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting, Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting, Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program, Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Basilea issues agenda for Annual General Meeting of Shareholders, Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis, Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany, Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom, Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe, GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program, Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor, Basilea provides clinical program updates, Final allocations of Basilea CHF 200 million senior convertible bonds, Basilea successfully places CHF 200 million senior convertible bonds, Basilea launches a senior convertible bond issue, Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553, Basilea announces that European Commission maintained isavuconazole's orphan drug status, Basilea announces filing of registration statement for a proposed offering in the United States, Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union, Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC, Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections, Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program, Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor, Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®, Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections, Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections, Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union, Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553, Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor, Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID, Basilea in-licenses targeted cancer therapy, Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis, Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe, Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis, Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia, Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany, Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis, Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models, Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis, Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study, Basilea reports that further subgroup and health economic analyses of isavuconazole phase 3 studies will be presented at IDWeek conference, Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis, Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC, European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review, Basilea appoints Chief Commercial Officer, Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014, Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider, Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections, Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis, Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections, Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis, Basilea announces start of phase 2a study with oncology drug candidate BAL101553, Basilea provides update on ceftobiprole's U.S. regulatory status, Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem, Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study, Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID, Basilea presents new data on its antibiotics pipeline at ECCMID.
Ristorante Dei Cappuccini, Amalfi Prezzi, Scuola Infanzia Regina Elena - Roma, Liceo Galileo Galilei, Tanqueray Ten Prezzo, Concerti Arena Di Verona 2020 Coronavirus, Santa Croce Lucca 2020, La Lotta Di Giacobbe Con L'angelo Gauguin, Stromboli Cosa Vedere, 7 Ottobre Festa, La Crisi Del 1929 E Il New Deal Mappa Concettuale, Chi Accolgono I Monaci Nella Foresteria, Arena Di Capua Capienza, Nati 19 Gennaio Caratteristiche,